The test, which will be developed using the companies' respective technologies, will be marketed by Biolidics following clinical validation.
The company posted higher total sales for the first half of its fiscal year 2020 on sales growth in both in Japan and internationally.
Called the "Ccheck Prostate Cancer Confirmation" test, Anixa's assay integrates flow cytometry and machine learning to identify evidence of cancer in a person's bloodstream.
Cytek said that the approval places the company on a path to offering a complete spectral flow cytometry solution — including instruments and reagents — to customers in China.
Rutgers researchers have developed a point-of-care tool that can rapidly assess the sensitivity of tumor cells to cancer drugs without staining or labeling.
The University of Arkansas researchers aim to commercialize the Cytophone platform, in development since 2003, by launching a startup in the next year.
The firm is starting a trial that it anticipates will lead to an application for marketing clearance with the US Food and Drug Administration by next year.
The test uses proprietary peptide analogs to detect overexpression of a peptide construct that binds to cancer cell membranes in urine or blood samples.
The clearance by the Chinese NMPA means the instrument can be used as a clinical diagnostic tool in hospitals, laboratories, and clinics in China.
Clinical researchers at AACR discussed a wide range of approaches focusing on several different potential use-cases in the detection or assessment of early cancers.